Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the FDA Office of Orphan Products Development was granted on August 6th, 2010.

26 Aug 2010

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.

26 Aug 2010

NeoStem responds to court ruling blocking government funding for embryonic stem cell research

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, commented today on the ruling this week of a U.S. District Court blocking the federal government from funding research involving human embryonic stem cells. In issuing a preliminary injunction, the judge said it violated a law first passed in 1996 prohibiting federal money for research where a human embryo is destroyed.

25 Aug 2010

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen's Homspera.

25 Aug 2010

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene Corporation today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer.

25 Aug 2010

Also in Global Health News: IDUs in Kenya; Haiti recovery; Pandemic preparedness; Somalia hunger; HIV in Mozambique; Strengthening immune system against HIV

In Kenya, "[i]ntravenous drug users (IDUs) have been largely ignored by the government's HIV programmes on the basis that drug-taking is illegal, but a new policy is being drafted with the aim of reducing HIV transmission among this high-risk group," IRIN/PlusNews reports. The article includes comments from Nicholas Muraguri, head of the National AIDS and Sexually Transmitted Infections Control Programme, who said that the policy would treat drug use as a health issue, not a criminal one.

25 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna (nilotinib) capsules have been approved with conditions in Canada as a new therapy for patients with CML, in the chronic phase (first phase) of the disease. Patients must be resistant to or intolerant of at least one prior therapy, including (Pr)Gleevec (imatinib mesylate), an established standard of care.

20 Aug 2010

Even low-level exposure to cigarette smoke affects gene function in lungs

Casual smokers may think that smoking a few cigarettes a week is "no big deal." But according to new research from physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, having an infrequent smoke, or being exposed to secondhand smoke, may be doing more harm than people may think. The findings may further support public smoking bans, say the authors.

20 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.

19 Aug 2010

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).

18 Aug 2010

Researcher unveils unique stem cell partnership that can lead to advances in regenerative medicine

A study led by a researcher at Albert Einstein College of Medicine of Yeshiva University has revealed a unique "partnership" between two types of bone marrow stem cells, which could lead to advances in regenerative medicine. The aim of regenerative medicine is to enable the body to repair, replace, restore or regenerate damaged or diseased cells, tissues and organs.

18 Aug 2010

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

Cryo-Cell International, Inc., one of the largest and most established leaders in stem cell innovation, today announced a research and development collaboration agreement with Monash University in Australia. The partnership will allow scientists from the University's Centre of Inflammatory Diseases to conduct pre-clinical studies using Cryo-Cell's proprietary C'elle menstrual stem cell technology (MenScs) to identify potential future therapies to treat autoimmune diseases such as multiple sclerosis.

18 Aug 2010

Aastrom Bioscience fourth quarter net loss decreases to $0.18 per share

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported operating results for the fourth quarter and fiscal year ended June 30, 2010.

18 Aug 2010

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Looking to gain further understanding about the impact of cancer on patients and families, The Cancer Institute of New Jersey (CINJ) is expanding its Quality and Outcomes in Cancer Care (QOCC) Research Program by welcoming nationally-recognized population science researcher Sharon Manne, PhD. Dr. Manne, who is the recipient of major grant awards from the National Institutes of Health (NIH) for her work in behavioral science, was most recently at the Fox Chase Cancer Center in Philadelphia. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

17 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

BAC, Octapharma enter licence agreement for G-CSF CaptureSelect custom affinity ligand

BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it has entered into a licence agreement with Octapharma (Lachen, Switzerland), an independent, global provider of human proteins for life-threatening diseases.

17 Aug 2010

Human adult stem cells can regenerate damaged heart tissue: Research

Mayo Clinic investigators, with Belgian collaborators, have demonstrated that rationally "guided" human adult stem cells can effectively heal, repair and regenerate damaged heart tissue. The findings called "landmark work" in an accompanying editorial appear in today's Journal of the American College of Cardiology.

17 Aug 2010

Bone Marrow News and Research

Further Reading

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

FDA grants LFB's recombinant anti-CD20 monoclonal antibody orphan drug status for CLL

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

NeoStem responds to court ruling blocking government funding for embryonic stem cell research

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Also in Global Health News: IDUs in Kenya; Haiti recovery; Pandemic preparedness; Somalia hunger; HIV in Mozambique; Strengthening immune system against HIV

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Tasigna receives approval for chronic myeloid leukemia in Canada

Even low-level exposure to cigarette smoke affects gene function in lungs

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Bolder BioTechnology receives $600,000 NIH SBIR grant to study long-acting IL-11 analog in ARS

Researcher unveils unique stem cell partnership that can lead to advances in regenerative medicine

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

Aastrom Bioscience fourth quarter net loss decreases to $0.18 per share

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

BAC, Octapharma enter licence agreement for G-CSF CaptureSelect custom affinity ligand

Human adult stem cells can regenerate damaged heart tissue: Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News